Another setback for Advaxis after Amgen walks away from major project

17 December 2018

New Jersey’s Advaxis (Nasdaq: ADXS) has suffered a near-40% blow to its share price after the firm revealed that Amgen (Nasdaq: AMGN) was tearing up a half-billion dollar collaboration to develop ADX-NEO.

Under the terms of the 2016 deal, Amgen was responsible for fully-funding clinical development of the investigational immuno-oncology therapy, which is designed to activate the immune system in response to certain mutations, or neoepitopes, unique to a particular tumor.

Advaxis quietly announced the end of the partnership via a filing with the US Securities and Exchange Commission, noting that Amgen was withdrawing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK